Subscribe for great stories in your community!
Hatfield-based Code Biotherapeutics has entered into a collaboration and option deal with Takeda with a potential value of $2 billion, writes John George for…
King of Prussia-based CSL Behring has joined forces with several other biopharmaceutical companies to develop a potential plasma-derived therapy to treat COVID-19…
Before we send you to this site, please subscribe to our daily newsletter.